Invention Grant
- Patent Title: N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
-
Application No.: US16438061Application Date: 2019-06-11
-
Publication No.: US11001578B2Publication Date: 2021-05-11
- Inventor: Rebecca Louise Davie , Hannah Joy Edwards , David Michael Evans , Simon Teanby Hodgson
- Applicant: KALVISTA PHARMACEUTICALS LIMITED
- Applicant Address: GB Wiltshire
- Assignee: KALVISTA PHARMACEUTICALS LIMITED
- Current Assignee: KALVISTA PHARMACEUTICALS LIMITED
- Current Assignee Address: GB Wiltshire
- Agency: BakerHostetler
- Priority: GB1421083 20141127
- Main IPC: A61K31/4439
- IPC: A61K31/4439 ; A61K31/445 ; A61K31/496 ; C07D413/14 ; C07D401/14 ; A61P9/00 ; C07D401/10 ; A61P43/00 ; C07D231/14 ; C07D401/06 ; C07D403/10 ; C07D409/14
Abstract:
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
Public/Granted literature
- US20190300517A1 N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors Public/Granted day:2019-10-03
Information query
IPC分类:
